コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ay were immediately prompted to practice and retest.
2 due to training still observable at a 1 week retest.
3 w noninvasive, rapid scanning with good test-retest.
4 is similar to the agreement on Stratus test-retest.
5 ssed by a masked examiner and confirmed by a retest.
6 uisition, and greater improvement at the 6 h retest.
7 ontrol), 25%, 50%, and 75%, and the function retested.
8 22.3% of men and 38.0% of nonpregnant women retested.
9 s of children (12 preterm, 12 controls) were retested.
10 toxic lesions of BLA or OFC, followed by RDT retesting.
11 ivity and high conversion/reversion rates on retesting.
12 onidine 0.15% for 8 weeks and designated for retesting.
13 ontrols from two centers; a subset underwent retesting.
14 udy period, 25% of which (n = 360) underwent retesting.
15 initially increased CTCs, 31 (10%) were not retested, 165 were assigned to arm B, and 123 were rando
16 iple metastases underwent 2 whole-body (test-retest) (18)F-NaF PET/CT scans 3 +/- 2 d apart from 1 of
17 rticipated in this study ((18)F-MNI-654 test-retest, 2 men; (18)F-MNI-659 test-retest, 4 men and 1 wo
18 weight +/- 2 [range, 34-37 mmol/kg]; for the retest, 37 mmol/kg +/- 1 [range, 35-39 mmol/kg]; P = .61
19 I-654 test-retest, 2 men; (18)F-MNI-659 test-retest, 4 men and 1 woman; (18)F-MNI-659 dosimetry, 2 me
25 during a baseline placebo run-in period and retested after 28-days of drug (n = 21) or placebo (n =
39 measurements were highly reproducible (test-retest), and both small-animal PET and beta-microprobes
40 +/- 0.52 mL/cm(3) (mean +/- SD; n = 4; test-retest), and the reproducibility in test-retest studies
42 ively in all animals and in a subset of test-retest animals using a network quantification approach.
45 d studies of chlamydia-infected men who were retested at a later date without having received treatme
47 1) reliability (stability of criteria during retesting, between raters, over time, and across setting
49 ted positive for cytomegalovirus (CMV), were retested by five different laboratories, each using a di
51 13 were treated with 1 g of azithromycin and retested by polymerase chain reaction (PCR) on days 14 a
52 The aim of this study was to determine test-retest characteristics and variability of SMGU within an
55 served with small-animal PET in the test and retest conditions on the one hand and the NAc and MK-801
56 nt change were defined as exceeding 95% test-retest confidence limits based upon the mean sensitivity
57 raclass correlation coefficient values (test-retest consistency) were greater than 0.92 for all regio
59 l groups; 90 participants were assigned to a retest control that did not complete the main outcome me
61 rted unnecessary ART costs were greater than retesting costs within 1 year using assumptions represen
64 these results was also observed in a second retest dataset, demonstrating the robustness of our find
65 dentified prospectively acquired PET/CT test-retest datasets of 74 patients from multicenter Merck an
66 dentified prospectively acquired PET/CT test-retest datasets of 74 patients from multicenter Merck an
78 te difference of the area of EZ loss on test-retest for the first grader was 0.12 +/- 0.10 mm(2), and
82 al consistency (Cronbach's test > 0.84, test-retest > 0.7), reliability (>0.9), and acceptability.
93 he samples in positive pool samples are then retested individually to identify the patients with the
95 ient or an informant before the test and the retest interviews, which were conducted from 4 hours to
102 a selected treatment (n = 3); second, a test-retest (n = 12) small-animal PET experiment (1 h scan; 2
106 lidation with experimental samples, (ii) DS2 retesting of case-defined clinical samples, and (iii) a
107 opsy for confirmation of disease process and retesting of estrogen receptor, progesterone receptor, a
114 of pregnant women with a positive test were retested, only 22.0% received a test-of-cure within the
116 3 LTBI screening strategies and the need for retesting patients with negative results at baseline.
117 data can be used to assess whether physician-retesting patterns are in line with established guidelin
123 h maximum stress perfusion and CFR, (2) test-retest precision in same subject, (3) stress perfusion a
125 healthy male subjects participated in a test-retest protocol with dynamic scans and metabolite-correc
129 scales in all clinical settings), high test-retest reliability (>0.76 for all domains), high respons
130 al consistency reliability (alpha=.85); test-retest reliability (ICC=.76); and convergent (r=.81 with
131 ility (Cronbach's alpha=0.81 vs. 0.88); test-retest reliability (intraclass correlation coefficient=0
132 sistent (Cronbach alpha=0.84), had good test-retest reliability (intraclass correlation coefficient=0
133 (Cronbach alpha coefficient, 0.84) and test-retest reliability (mean percentage variation, 0.92).
134 .97), feasibility (97% completion), and test-retest reliability (r = 0.71; 95% CI, 0.59-0.80) were de
136 sity hospital; voxel-based morphometry; test-retest reliability analysis of striatal activations in a
137 resampling of words does not affect the test-retest reliability and diagnostic value of the CNC word
142 ch's alpha and item-total correlations; test-retest reliability by intraclass correlation coefficient
145 Field Trials were conducted by using a test-retest reliability design with a stratified sampling app
146 SLS I and II (N=300), we evaluated the test-retest reliability for FVC% predicted (FVC%; screening v
150 he aim of this study was to measure the test-retest reliability of (11)C-N,N-dimethyl-2-(2'-amino-4'-
151 development, descriptive statistics,and test-retest reliability of cross-cutting symptom measures pro
154 addition, the known-groups validity and test-retest reliability of the AAS were found to be good.
156 compared to standard tones, and a high test-retest reliability of the P300 amplitude (r > = .74).
169 ability (i.e., internal consistency and test-retest reliability) and validity (i.e., convergent, conc
170 the intraclass correlation coefficient (test-retest reliability) for repeated questionnaires among st
173 CAINS structure, interrater agreement, test-retest reliability, and convergent and discriminant vali
174 rtest agreement, intergrader agreement, test-retest reliability, and the time taken to grade using th
176 esults demonstrated that, ensuring high data retest reliability, four cingulate subregions discerning
177 ility of this phenotype, we studied its test-retest reliability, its potential brain structural contr
178 coronary artery disease (CAD) with high test-retest reliability, predictive power, and responsiveness
179 ontained sufficient data on inter-rater/test-retest reliability, responsiveness, and feasibility.
180 ility of data once collected, including test-retest reliability, split-half reliability, and Cronbach
192 ency, (Cronbach's alpha coefficient and test-retest), reliability (intraclass correlation coefficient
193 ed with trait anxiety scores (P = .04), test-retest reliable (intraclass correlation coefficient = 0.
196 and coefficients of variation (COV) and test-retest repeatability as visualized by Bland-Altman analy
201 es of SUVs: SUV, SUVAUC, and SUVTBR The test-retest repeatability of these metrics, as well as metabo
202 ories, we have designed and completed a test-retest repeatability study for differential HDX-MS exper
204 fied with SUVmax, SUVmean, and SUVtotal Test-retest repeatability was assessed using Bland-Altman ana
205 sing both common and novel measures for test-retest repeatability, however, the quick CSF delivers mo
208 ree separate analyses were performed: a test-retest reproducibility analysis, where each of the first
211 ced diffusion MRI has good to excellent test-retest reproducibility in both human cTBI patients and c
222 Four volunteers (2 men, 2 women) underwent retest scanning, with a mean interscan interval of 37 d.
225 background, was 5.7 and 6.1 mL for test and retest scans, respectively, with a relative LOA limit of
228 ical P value CritIndex, such that 5% of test-retest series showed significant deterioration with P <
229 confirmed that performance of the task at a retest session after sleep significantly increased compa
230 ace recognition memory that is stable across retest sessions and correlates strongly with loss of hip
238 ts were enrolled, all of whom had pathologic retesting that confirmed HER2-negative primary breast ca
239 neralized SAD and healthy control groups; 2) retested the findings in an independent clinical sample;
244 eading to aversive emotional experiences, we retested two of these patients (B.G. and A.M.) to examin
245 D of mean percentage change between test and retest using the PERSI reference region was 2.22% for a
247 nstrated satisfactory reliability, with test-retest VA scores having a mean difference of 0.001 (SD +
251 es take into account expected localized test-retest variabilities in sensitivity, and trend-based ana
252 diameter and vertical diameter had low test-retest variabilities of 8.9%, 9.5%, and 9.6%, respective
253 owed excellent reproducibility of BPND (test-retest variability < 10%) in the nAChR-rich brain region
254 (Akaike preference, 43.6%), acceptable test-retest variability (12%), no dependence on perfusion cha
258 Peek Acuity was compared, in terms of test-retest variability and measurement time, with the Snelle
260 clinical studies including analysis of test-retest variability are essential to determine sensitivit
261 -monitoring device by measuring the device's retest variability at 2 months in a cohort of 43 patient
262 rformance was evaluated with respect to test-retest variability in a phase 2 study of 21 subjects (5-
266 orting noninvasive quantification, with test-retest variability less than 10% and intraclass correlat
270 he aim of this study was to examine the test-retest variability of (123)I-CLINDE binding in healthy s
272 right lung regions of interest, with a test-retest variability of -6% (MA1, n = 1) or -1% +/- 14% (E
274 s consistent with published data on the test-retest variability of acuities measured using 5-letter-p
277 al for (18)F-FPEB; it showed acceptable test-retest variability of nondisplaceable binding potential
281 r binding potential (BPND and BPP), the test-retest variability was good in regions of moderate and h
285 atched that from the bolus application (test-retest variability, 1.1% +/- 24.7%), which was not the c
293 e also demonstrated high reliability at test-retest with narrow limits of agreement and no statistica
294 say and been found to be negative, should be retested with a fluorescence-activated cell sorting assa
296 HOTV letter protocol without correction, and retested with full cycloplegic correction when retest cr
297 specimens from "seronegative" patients were retested with recombinant human AQP4-based assays, inclu
299 of borderline high cholesterol patients are retested within the 3 year recommended period, however l
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。